<bill session="115" type="h" number="6576" updated="2023-01-11T13:41:55Z">
  <state datetime="2018-07-26">REFERRED</state>
  <status>
    <introduced datetime="2018-07-26"/>
  </status>
  <introduced datetime="2018-07-26"/>
  <titles>
    <title type="display">Drug-Price Transparency in Communications Act</title>
    <title type="official" as="introduced">To require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.</title>
    <title type="short" as="introduced">Drug-Price Transparency in Communications Act</title>
  </titles>
  <sponsor bioguide_id="S001145"/>
  <cosponsors/>
  <actions>
    <action datetime="2018-07-26">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-07-26" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2018-07-27">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="115" type="s" number="2157" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-20T19:52:14Z" status="Introduced in House">Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.</summary>
</bill>
